Parallel Advisors, LLC Viking Therapeutics, Inc. Transaction History

Parallel Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$17.4 - $94.5 $3,427 - $18,616	197 New	197 $16,000
Q2 2022 Aug 01, 2022	SELL	$2.11 - $3.15 $3,070 - $4,583	-1,455 Reduced 93.69%	98 $0
Q2 2020 Jul 16, 2020	BUY	$4.35 - $8.08 $6,755 - $12,548	1,553 New	1,553 $11,000
Q1 2020 Apr 27, 2020	SELL	$3.45 - $7.95 $5,409 - $12,465	-1,568 Closed	0 $0
Q3 2019 Nov 01, 2019	BUY	$6.55 - $8.6 $10,270 - $13,484	1,568 New	1,568 $11,000
Q4 2018 Feb 05, 2019	SELL	$7.16 - $16.21 $0 - $0	0 Closed	0 $0
Q3 2018 Nov 01, 2018	BUY	$9.7 - $19.65 $0 - $0	0 New	0 $0

466

65.9M

6.24M

2.97M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.59B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.